The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 21, 2023
Filed:
Dec. 29, 2020
Applicant:
Unm Rainforest Innovations, Albuquerque, NM (US);
Inventors:
Vojo P. Deretic, Placitas, NM (US);
Jia Cassano, Albuquerque, NM (US);
Bhawana Bissa, Albuquerque, NM (US);
Assignee:
UNM RAINFOREST INNOVATIONS, Albuquerque, NM (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4164 (2006.01); A61K 31/4184 (2006.01); A61K 31/438 (2006.01); A61K 31/133 (2006.01); A61K 31/198 (2006.01); A61K 31/155 (2006.01); A61K 31/4439 (2006.01); A61K 31/585 (2006.01); A61K 31/7004 (2006.01); A61K 31/618 (2006.01); A61K 31/4365 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/437 (2006.01); A61K 31/485 (2006.01); A61K 31/4545 (2006.01); A61K 31/4418 (2006.01); A61K 31/192 (2006.01); A61K 31/58 (2006.01); A61K 31/365 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 31/133 (2013.01); A61K 31/155 (2013.01); A61K 31/192 (2013.01); A61K 31/198 (2013.01); A61K 31/365 (2013.01); A61K 31/4164 (2013.01); A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/438 (2013.01); A61K 31/4365 (2013.01); A61K 31/4418 (2013.01); A61K 31/4545 (2013.01); A61K 31/485 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01); A61K 31/58 (2013.01); A61K 31/585 (2013.01); A61K 31/618 (2013.01); A61K 31/7004 (2013.01);
Abstract
The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.